India, Nov. 4 -- Novo Nordisk A/S (NVO,NOVOB.CO,NOV.DE) reported third quarter net profit of 16.74 billion Danish kroner, a decline of 16% year-over-year. Earnings per share/ ADR was 3.79 kroner, down 16%. Adjusted net profit was 25.60 billion kroner, down 12% from last year. Adjusted diluted earnings per share/ADR was 5.79 kroner, a decline of 12%. Reported operating profit decreased by 9% at CER, reflecting non-cash impairment charges in the quarter, related to ziltivekimab and right-sizing of manufacturing network. Adjusted operating profit was 31.72 billion Danish kroner, up 27% at CER, driven by GLP-1 sales growth and a favourable comparison base following 9 billion kroner of company-wide transformation costs recognised in third quarte...